Thanks for your “glass half empty “ thoughts on the poster. Because as we know, the FDA has dozens of very promising AD candidates lined up. Especially all those Amyloid prospects.
Hnbdger1 dont forget about the one they just approved without absolutely any proof of efficacy….it just reduces plaque (by liquefying it?) and even then the body can’t necessarily rid itself of the by-product possibly causing many of the bad side effects.
Floating down a creek without any oars in the boat.
Because as we know, the FDA has dozens of very promising AD candidates lined up. Especially all those Amyloid prospects.
Nice thought but that won't help put 2-73 over the stat sig line. I share Investor2014's caution as to drawing too many conclusions from the poster presentation